This pattern may reflect inflammation- and hypoxia-driven activation of endothelin-1 and the renin–angiotensin–aldosterone system, leading to significant vasoconstriction, pulmonary hypertension, and eGFR decline with evolving CKD. This evidence concerns the gene EDN1 and pulmonary hypertension.